Drug-induced thrombosis: An update

Drug Safety

Volumn 36, Issue 8, 2013, Pages 585-603

  Ramot, Yuval ^a   Nyska, Abraham ^b,c   Spectre, Galia ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Consultant in Toxicologic Pathology ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ALPHA INTERFERON; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CISPLATIN; CLOZAPINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; GEMTUZUMAB; HEPARIN; IMMUNOGLOBULIN; METFORMIN; MITOMYCIN; OLANZAPINE; PACLITAXEL; QUETIAPINE; QUININE; RAPAMYCIN; RETINOIC ACID; RISPERIDONE; ROFECOXIB; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTICOAGULATION; AUTOIMMUNE DISEASE; BLOOD CLOTTING; BLOOD FLOW; BLOOD VISCOSITY; CARDIOTOXICITY; DEEP VEIN THROMBOSIS; DRUG ELUTING STENT; DRUG INDUCED THROMBOSIS; DRUG SAFETY; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; EPHEDRA; ERYTHROCYTE; FIBRINOLYSIS; GENETIC PREDISPOSITION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPOMAGNESEMIA; KIDNEY INJURY; LEUKOCYTE; LYMPHATIC LEUKEMIA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK FACTOR; SECRETION (PROCESS); STENT THROMBOSIS; SUBENDOTHELIUM; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMOSTASIS; HUMANS; MODELS, CARDIOVASCULAR; THROMBOSIS;

EID: 84881156299     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0054-6     Document Type: Review

References (221)

1. Zbinden G. Evaluation of thrombogenic effects of drugs. Annu Rev Pharmacol Toxicol. 1976;16:177-88.
2. Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug Saf. 2005;28(9):803-16.
3. Sachdeva R, Sivasankaran S, Fishman RF, Zarich SW, McPherson CA. Coronary thrombosis related to use of Xenadrine RFA. Tex Heart Inst J. 2005;32(1):74-7.
4. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558-60.
5. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med. 2007;356(24):2448-51.
6. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl. 1):I9-16.
7. Ramot Y, Nyska A. Drug-induced thrombosis: experimental, clinical, and mechanistic considerations. Toxicol Pathol. 2007;35(2):208-25.
8. Schultze AE, Walker DB, Turk JR, Tarrant JM, Brooks MB, Pettit SD. Current practices in preclinical drug development: gaps in hemostasis testing to assess risk of thromboembolic injury. Toxicol Pathol. 2013;41(3):445-53.
9. Blann AD, Lip GY. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res. 2001;101(4):321-7.
10. Slauson D, Cooper B. Mechanisms of disease: a textbook of comparative general pathology. 3rd ed. St. Louis: Mosby; 2002.
11. Blann AD. How a damaged blood vessel wall contributes to thrombosis and hypertension. Pathophysiol Haemost Thromb. 2003;33(5-6):445-8.
12. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-59.
13. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681-703.
14. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178-89.
15. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett. 2005;579(15):3303-9.
16. Lowe GD. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003;33(5-6):455-7.
17. Wootton DM, Ku DN. Fluid mechanics of vascular systems, diseases, and thrombosis. Annu Rev Biomed Eng. 1999;1:299-329.
18. Dormandy JA, Edelman JB. High blood viscosity: an aetiological factor in venous thrombosis. Br J Surg. 1973;60(3):187-90.
19. Kropelin T, Gospos C, Papacaralampous X, Freudenberg N. The risk liability of nephrotropic contrast media: clinical and experimental results. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1983;118:129-42.
20. Palomaki H, Muuronen A, Raininko R, Piilonen A, Kaste M. Administration of nonionic iodinated contrast medium does not influence the outcome of patients with ischemic brain infarction. Cerebrovasc Dis. 2003;15(1-2):45-50.
21. Raininko R. Morphologic endothelial response to meglumine diatrizoate: an electron-microscopic study. Angiology. 1981;32(11):733-41.
22. Aliev G, Obrenovich ME, Seyidova D, Rzayev NM, Aliyev AS, Raina AK, et al. X-ray contrast media induce aortic endothelial damage, which can be prevented with prior heparin treatment. J Submicrosc Cytol Pathol. 2003;35(3):253-66.
23. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007-15.
24. Mare K, Violante M. Pulmonary edema induced by contrast medium: a comparative investigation in the rat following high intravenous doses of one ionic (diatrizoate) and non-ionic (metrizamide) contrast medium. Acta Radiol Diagn (Stockh). 1983;24(6):481-5.
25. Mare K, Violante M. Pulmonary edema induced by high intravenous doses of diatrizoate in the rat. Acta Radiol Diagn (Stockh). 1983;24(5):419-24.
26. Tsuda N. In situ quantification of endothelial cell damage caused by iodinated contrast media using a rat vena cava model. Eur J Radiol. 2012;81(5):879-84.
27. Gospos C, Freudenberg N, Staubesand J, Mathias K, Papacharlampos X. The effect of contrast media on the aortic endothelium of rats. Radiology. 1983;147(3):685-8.
28. Gospos C, Koch HK, Mathias K, Seemann W, Tan KG, Papacharalampous X. Scanning electron microscopic (SEM) studies on the effect of x-ray contrast media on aortic endothelium in the rat. Invest Radiol. 1983;18(4):382-6.
29. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 2003;42(4):304-8.
30. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem. 2006;4(1):1-5.
31. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol. 2007;14(5):468-80.
32. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779-802.
33. Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007;33(4):355-64.
34. Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225(4):211-21.
35. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5(10):2441-7.
36. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2008;8(4):527-40.
37. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406-13.
38. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol. 1993;71(Pt 6):571-81.
39. Brisse H, Orbach D, Lassau N, Servois V, Doz F, Debray D, et al. Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature. Eur J Cancer. 2004;40(18):2659-66.
40. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer. 2003;98(8):1578-86.
41. Venkatraman S, Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J Control Release. 2007;120(3):149-60.
42. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116(17):1952-65.
43. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701-5.
44. Jen CJ, Dong HP, Chen H, Wing LC, Tang MJ, Chang WC, et al. Platelet adhesion following the administration of tissue-type plasminogen activator and its reversal by vitamin E in rats. Thromb Haemost. 1996;75(1):101-6.
45. Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost. 2009;7(1):14-20.
46. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-29.
47. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, et al. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol. 2008;19(4):521-8.
48. Doepp F, Sanad W, Schreiber SJ, Baumann G, Borges AC. Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke. Cardiovasc Ultrasound. 2005;3:14.
49. Fassbender K, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30(10):2101-4.
50. Conforti G, Dominguez-Jimenez C, Ronne E, Hoyer-Hansen G, Dejana E. Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer. Blood. 1994;83(4):994-1005.
51. Shi GY, Hau JS, Wang SJ, Wu IS, Chang BI, Lin MT, et al. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells. J Biol Chem. 1992;267(27):19363-8.
52. Bombeli T, Muller M, Straub PW, Haeberli A. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med. 1996;127(6):621-34.
53. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors: a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75(2):368-71.
54. Tolcher AW, Giusti RM, O'Shaughnessy JA, Cowan KH. Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest. 1995;13(2):188-92.
55. de Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. 1991;338(8765):517-8.
56. Stehle B, Weiss C, Ho AD, Hunstein W. Serum levels of tumor necrosis factor alpha in patients treated with granulocyte-macrophage colony-stimulating factor. Blood. 1990;75(9):1895-6.
57. Pogrebniak HW, Matthews W, Pass HI. Chemotherapy amplifies production of tumor necrosis factor. Surgery. 1991;110(2):231-7.
58. Micallef M. Immunoregulatory cytokine production by tumor-bearing rat spleen cells and its modulation by bleomycin. Anticancer Drugs. 1993;4(2):213-22.
59. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs. 1994;5(6):607-14.
60. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71(1):1-8.
61. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant. 2004;33(2):171-6.
62. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-35.
63. Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005;105(11):4463-9.
64. Vane J. Towards a better aspirin. Nature. 1994;367(6460):215-6.
65. US FDA. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product, 30 Sep 2004. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2004/ucm108361.htm. Accessed 12 April 2013.
66. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res. 2005;42(4):312-24.
67. Toborek M, Kaiser S. Endothelial cell functions: relationship to atherogenesis. Basic Res Cardiol. 1999;94(5):295-314.
68. Meyer CH, Schmidt JC, Rodrigues EB, Mennel S. Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). Ophthalmologica. 2005;219(4):243-7.
69. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-8.
70. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl.):234S-64S.
71. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl.):e637-68S.
72. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676-88.
73. Duperray A, Tranqui L, Alix JL, Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol. 1988;37(24):4753-7.
74. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50(4):1255-61.
75. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33(5):821-8.
76. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther. 2006;5(12):3303-11.
77. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-71.
78. Corso A, Lorenzi A, Terulla V, Airo F, Varettoni M, Mangiacavalli S, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83(9):588-91.
79. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6):879-87.
80. Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004;2(2):327-34.
81. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96(2):313-21.
82. McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. Non-artheritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol. 2006;90(2):154-7.
83. Tripathi A, O'Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol. 2000;84(8):934-5.
84. Arora RR, Timoney M, Melilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med. 1999;341(9):700.
85. Morgan JC, Alhatou M, Oberlies J, Johnston KC. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. Neurology. 2001;57(9):1730-1.
86. Rufa A, Cerase A, Monti L, Dotti MT, Giorgio A, Sicurelli F, et al. Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. J Neurol Sci. 2007;260(1-2):293-5.
87. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol. 2002;39(4-5):213-23.
88. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol. 2002;14(2):121-9.
89. Reilly MP, McKenzie SE. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol. 2002;9(5):395-400.
90. Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007;50(12):1138-43.
91. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007;33(8):787-97.
92. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica. 2007;92(7):878-80.
93. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol. 2004;77(3):316-8.
94. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8(5):286-93.
95. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102-11.
96. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987;24(3):161-77.
97. Aguejouf O, Malfatti E, Doutremepuich F, Doutremepuich C. Thrombogenic potential of contrast media in an experimental model of laser-induced thrombosis. Thromb Res. 2000;100(3):167-77.
98. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98(7):1514-20.
99. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood. 1991;78(1):154-62.
100. Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol. 1997;54(3):225-32.
101. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95(9):2983-9.
102. Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62(1):3-8.
103. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104(16):1894-8.
104. Kurne A, Ertugrul A, Anil Yagcioglu AE, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry. 2004;26(6):481-3.
105. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16(11):765-76.
106. Axelsson S, Hagg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007;34(8):775-80.
107. Hagg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics: a study of the WHO database of adverse drug reactions. Drug Saf. 2008;31(8):685-94.
108. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, Kontek B. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry. 2010;11(2 Pt 2):268-75.
109. Dietrich-Muszalska A, Rabe-Jablonska J, Olas B. The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro. World J Biol Psychiatry. 2010;11(2 Pt 2):293-9.
110. Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Hentschel B, Gertz HJ, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol. 2003;23(5):479-83.
111. Reuwer AQ, Nieuwland R, Fernandez I, Goffin V, van Tiel CM, Schaap MC, et al. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost. 2009;101(6):1119-27.
112. Al-Shekhlee A, Oghlakian G, Katirji B. A case of cyclosporine-induced dural sinus thrombosis. J Thromb Haemost. 2005;3(6):1327-8.
113. Fishman SJ, Wylonis LJ, Glickman JD, Cook JJ, Warsaw DS, Fisher CA, et al. Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res. 1991;51(2):93-8.
114. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146(6):882-93.
115. Ramot Y, Steiner M, Morad V, Leibovitch S, Amouyal N, Cesta MF, et al. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology. 2010;4(1):98-105.
116. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol. 2005;45(11):1753-6.
117. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-306.
118. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol. 1999;6(2):76-82.
119. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89(4):1121-32.
120. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005;62(9):971-88.
121. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107(2):300-2.
122. Brown G, Giffin H. The treatment of polycytemia with phenylhydrazine. Arch Int Med. 1926;38:321.
123. Ramot Y, Koshkaryev A, Goldfarb A, Yedgar S, Barshtein G. Phenylhydrazine as a partial model for beta-thalassaemia red blood cell hemodynamic properties. Br J Haematol. 2008;140(6):692-700.
124. Falanga A, Marchetti M, Barbui T. All-trans-retinoic acid and bleeding/thrombosis. Pathophysiol Haemost Thromb. 2003;33(Suppl. 1):19-21.
125. Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol. 1996;93(2):360-6.
126. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282(28):20047-51.
127. Nishiwaki H, Ogura Y, Miyamoto K, Hiroshiba N, Hamada M, Honda Y. Prednisolone, platelet-activating factor receptor antagonist, or superoxide dismutase reduced leukocyte entrapment induced by interferon alpha in retinal microcirculation. Invest Ophthalmol Vis Sci. 1997;38(5):811-6.
128. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1998;93(12):2441-4.
129. Okuse C, Adachi K, Katakura Y, Matsunaga K, Ishii T, Matsumoto N, et al. A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C. J Gastroenterol. 2006;41(12):1231-6.
130. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24(7):491-501.
131. Lowe GD. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med. 2004;256(5):361-74.
132. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb Haemost. 1999;81(6):918-24.
133. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability: results from the Prospective Collaborative Danish Climacteric Study. BJOG. 2003;110(6):541-7.
134. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab. 2003;17(1):149-64.
135. Martinelli I, Battaglioli T, Mannucci PM. Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. Pharmacogenetics. 2003;13(10):589-94.
136. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999;354(9195):2036-40.
137. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004;103(3):927-33.
138. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996;156(16):1806-10.
139. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993;4(6):935-42.
140. Glueck CJ, Goldenberg N, Budhani S, Lotner D, Abuchaibe C, Gowda M, et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res. 2011;158(4):225-34.
141. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992;7(3):235-9.
142. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-33.
143. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2(8500):217-8.
144. Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714-21.
145. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30-4.
146. Stratta P, Canavese C, Schinco PC, Montaruli B, Giorda L, Bessone P, et al. Intravenous immunoglobulin contains detectable amounts of antiphospholipid antibodies. Br J Haematol. 1997;96(4):872-3.
147. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol. 2007;17(6):546-7.
148. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77(4):331-5.
149. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol. 1970;7(3):212-6.
150. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 1982;68(1):39-42.
151. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD.
152. Kwaan HC, McFadzean AJ. The inhibition of clot lysis by corticotrophin. Lancet. 1956;270(6908):136-7.
153. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93(8):2506-14.
154. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant. 1999;23(10):991-6.
155. Rella C, Coviello M, Giotta F, Maiello E, Colavito P, Colangelo D, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996;40(2):151-9.
156. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6(2):276-81.
157. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 1990;89(1):25-8.
158. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989;63(7):1303-7.
159. Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost. 2007;33(4):427-34.
160. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777-85.
161. Maki A, Shirato C, Ohguchi M, Aoki N, Ochiai N, Taguchi S, et al. Mechanism of rethrombosis after thrombolytic therapy: angioscopic findings and investigation of the coagulation system in dogs. Angiology. 1998;49(6):447-53.
162. Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost. 1999;82(1):104-8.
163. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004;10(3):225-32.
164. van Giezen JJ, Brakkee JG, Dreteler GH, Bouma BN, Jansen JW. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis. 1994;5(2):249-55.
165. Brown JE, Olujohungbe A, Chang J, Ryder WD, Morganstern GR, Chopra R, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol. 2000;110(4):1010-2.
166. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98(4):1252-4.
167. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97(10):3300-2.
168. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642-53.
169. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2(1):1-12.
170. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985;56(12):2765-70.
171. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science. 1980;208(4440):198-200.
172. Sapru H, Theoharides T. Pharmacology (essentials of basic science). II ed. Boston: Little, Brown; 1996.
173. Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. Med J Aust. 1997;167(4):199-200.
174. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol. 1999;37(4):485-9.
175. Vaziri ND, Ritchie C, Brown P, Kaupke J, Atkins K, Barker S, et al. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. ASAIO Trans. 1989;35(3):505-8.
176. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-90.
177. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 2006;12(7):793-800.
178. Ishak R, Loh Chooi K. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit. Malays J Reprod Health. 1991;9(1):5-8.
179. Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH. Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol. 2005;78(3):216-20.
180. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177-93.
181. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy. 2002;22(12):1638-41.
182. Lee YJ, Shin JU, Lee J, Kim K, Kim WS, Ahn JS, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci. 2007;22(4):758-61.
183. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res. 2007;19(2):139-48.
184. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83-90.
185. El-Sayed M, Omar A, Lin X. Post-exercise alcohol ingestion perturbs blood haemostasis during recovery. Thromb Res. 2000;99(6):523-30.
186. El-Sayed MS, Ali N, El-Sayed Ali Z. Interaction between alcohol and exercise: physiological and haematological implications. Sports Med. 2005;35(3):257-69.
187. Baer HJ, Glynn RJ, Hu FB, Hankinson SE, Willett WC, Colditz GA, et al. Risk factors for mortality in the nurses' health study: a competing risks analysis. Am J Epidemiol. 2011;173(3):319-29.
188. Hansen-Krone IJ, Braekkan SK, Enga KF, Wilsgaard T, Hansen JB. Alcohol consumption, types of alcoholic beverages and risk of venous thromboembolism: the Tromso Study. Thromb Haemost. 2011;106(2):272-8.
189. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59(1):20-3.
190. Pantel J, Schroder J, Eysenbach K, Mundt C. Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pharmacopsychiatry. 1997;30(3):109-11.
191. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677-82.
192. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356(9237):1219-23.
193. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
194. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18(10):2169-78.
195. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255-67.
196. Mano MS, Guimaraes JL, Sutmoller SF, Reiriz AB, Sutmoller CS, Di Leo A. Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J. 2006;124(6):343-5.
197. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021-4.
198. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168-71.
199. Kurt M, Shorbagi A, Altundag K, Elkiran T, Gullu I, Kansu E. Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia. Am J Hematol. 2005;80(3):213-5.
200. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3(9):1985-92.
201. Reddy P, Chow MS. Safety and efficacy of antiestrogens for prevention of breast cancer. Am J Health Syst Pharm. 2000;57(14):1315-22 (quiz 23-5).
202. Dunkley S, Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost. 2007;5(6):1323-5.
203. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-85.
204. Heesch CM, Wilhelm CR, Ristich J, Adnane J, Bontempo FA, Wagner WR. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000;83(6):688-95.
205. Wright NM, Martin M, Goff T, Morgan J, Elworthy R, Ghoneim S. Cocaine and thrombosis: a narrative systematic review of clinical and in-vivo studies. Subst Abuse Treat Prev Policy. 2007;2:27.
206. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345(5):351-8.
207. Pislaru S, Pislaru C, Szilard M, Arnout J, Van de Werf F. In vivo effects of contrast media on coronary thrombolysis. J Am Coll Cardiol. 1998;32(4):1102-8.
208. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007;66(10):1296-304.
209. Starke RM, Kim GH, Fernandez A, Komotar RJ, Hickman ZL, Otten ML, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9):2617-21.
210. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708-14.
211. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535-55.
212. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133-7.
213. Luna E, Cerezo I, Collado G, Martinez C, Villa J, Macias R, et al. Vascular thrombosis after kidney transplantation: predisposing factors and risk index. Transplant Proc. 2010;42(8):2928-30.
214. Gangireddy C, Rectenwald JR, Upchurch GR, Wakefield TW, Khuri S, Henderson WG, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007;45(2):335-41 (discussion 41-2).
215. Lin HY, Chung CY, Chang CS, Wang ML, Lin JS, Shen MC. Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. J Formos Med Assoc. 2007;106(9):774-8.
216. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008;23(10):1761-7.
217. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465-73.
218. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83(5A):35C-44C.
219. Bennett CL, Kiss JE, Weinberg PD, Pinevich AJ, Green D, Kwaan HC, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998;352(9133):1036-7.
220. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA. 1999;281(9):806-10.
221. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.